- Home
- CMRX
CMRX
Chimerix Inc.
as 07-26-2024 4:00pm EST
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 79.1M | IPO Year: | 2013 |
| Target Price: | $8.50 | AVG Volume (30 days): | 228.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $1.30 | Next Earning Date: | 08-09-2024 |
| Revenue: | $41,000 | Revenue Growth: | -99.88% |
| Revenue Growth (this year): | 2324.07% | Revenue Growth (next year): | -61.04% |
Stock Insider Trading Activity of Chimerix Inc. (CMRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Andriole Michael T. | CMRX | PRESIDENT AND CEO | Feb 14 '24 | Sell | $1.04 | 1,744 | $1,809.40 | 447,021 | SEC Form 4 |
| LaSpaluto Michelle | CMRX | CHIEF FINANCIAL OFFICER | Feb 14 '24 | Sell | $1.04 | 1,940 | $2,022.64 | 110,999 | SEC Form 4 |
| Jakeman David | CMRX | VP OF FINANCE AND ACCOUNTING | Feb 14 '24 | Sell | $1.04 | 2,660 | $2,776.77 | 141,232 | SEC Form 4 |
Latest Chimerix Inc. News
CMRX Breaking Stock News: Dive into CMRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 days ago
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Insider Monkey
3 months ago
Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript
GuruFocus.com
3 months ago
Chimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
Thomson Reuters StreetEvents
3 months ago
Q1 2024 Chimerix Inc Earnings Call
Associated Press Finance
3 months ago
Chimerix: Q1 Earnings Snapshot
GlobeNewswire
3 months ago
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
GlobeNewswire
3 months ago
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
Compare CMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMRX Chimerix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.